Tiberiu A Pana1, Jesus A Perdomo-Lampignano1, Phyo K Myint2,3. 1. Ageing Clinical and Experimental Research Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK. 2. Ageing Clinical and Experimental Research Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK. phyo.myint@abdn.ac.uk. 3. School of Medicine, Medical Sciences and Nutrition, Room 4.013, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK. phyo.myint@abdn.ac.uk.
Abstract
PURPOSE OF REVIEW: As one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group. RECENT FINDINGS: Several recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis. Nonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.
PURPOSE OF REVIEW: As one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the strokepatient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group. RECENT FINDINGS: Several recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis. Nonagenarian strokepatients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.
Authors: Amar Rash; Tom Downes; Robin Portner; Wilf W Yeo; Nicolette Morgan; Kevin S Channer Journal: Age Ageing Date: 2006-12-15 Impact factor: 10.668
Authors: P A Ringleb; Ch Schwark; M Köhrmann; S Külkens; E Jüttler; W Hacke; P D Schellinger Journal: J Neurol Neurosurg Psychiatry Date: 2006-10-20 Impact factor: 10.154
Authors: Luigi Giusto Spagnoli; Alessandro Mauriello; Giuseppe Sangiorgi; Stefano Fratoni; Elena Bonanno; Robert S Schwartz; David G Piepgras; Raimondo Pistolese; Arnaldo Ippoliti; David R Holmes Journal: JAMA Date: 2004-10-20 Impact factor: 56.272
Authors: Jessica E Simon; David L Sandler; J H Warwick Pexman; Michael D Hill; Alastair M Buchan Journal: Age Ageing Date: 2004-03 Impact factor: 10.668